Reactivation of Latent Herpesvirus 6 in CAR-T Cancer Therapy

Researchers have discovered that latent human herpesvirus 6 (HHV-6) can be reactivated in CAR T cells, a type of immune cell used in cancer immunotherapy. The study utilized genomic data and sequencing data to investigate the reactivation of HHV-6 in CAR T cells. The findings highlight the importance of understanding viral reactivation in the context of CAR T cell therapy and its potential implications for patient outcomes.